Britain's GSK lifts outlook after drug sales help it beat forecasts

Oct 27, 2021 · Britain's GSK raised its annual profit outlook on Wednesday after better-than-expected third-quarter results on strong sales of key drugs and cost cutting ahead of a …

CouponFollow Extension

$1
OFF

Britain's GSK Lifts Profit Outlook After Sales Help It Beat Forecasts

1 week from now

A new chair of the consumer healthcare business is expected to be announced before the end of the year, GSK said. ($1 = 0.7272 pounds) Britain's GSK lifts profit outlook after sales help it …

investing.com

22%
OFF

GSK Lifts Guidance After HIV, Cancer Treatments Boost Sales — …

1 week from now

Jul 31, 2024 · GSK's specialty medicines sales grew 22% to GBP3.02 billion, beating consensus of GBP2.86 billion. However, vaccine sales of nearly GBP2 billion undershot forecasts of …

morningstar.com

9%
OFF

Trending: GSK Hikes Its Sales And Earnings Outlook After

1 week from now

Jan 31, 2024 · GSK's shares have slipped 0.9% to 1,523.6 pence, though they are up 4.9% in the last month, and 6.8% over the last year--well ahead of the 1% fall over the month and 1.5% …

morningstar.com

$9.18
OFF

GSK Raises Profit Outlook On Strong Vaccine, HIV Drug Sales

1 week from now

May 1, 2024 · It reported a first-quarter profit of 43.1 pence per share on sales of 7.36 billion pounds ($9.18 billion), beating analysts' forecasts for 37.3 pence earnings and sales of 7.07 …

reuters.com

FAQs about Britain's GSK lifts outlook after drug sales help it beat forecasts Coupon?

Why did GSK raise its annual profit outlook?

REUTERS/Matthew Childs Purchase Licensing Rights Oct 27 (Reuters) - Britain's GSK (GSK.L) raised its annual profit outlook on Wednesday after better-than-expected third-quarter results on strong sales of key drugs and cost cutting ahead of a planned split next year, in a boost to its shares. ...

What's behind GSK's improved outlook?

GSK's improved outlook rests on expected pharmaceuticals sales growth, despite a forecast for lower vaccine sales as a surge in the coronavirus Delta variant delayed an expected recovery, including for its key shingles shot. ...

Why did GSK raise its guidance?

Photo: Vivian Wan/Bloomberg News GSK GSK 0.93% upgraded its sales and earnings forecasts for the year after HIV and cancer treatments lifted sales ahead of analysts’ expectations in the second quarter, making it the latest major pharmaceutical company to raise its guidance. ...

What will GSK expect in 2024?

GSK said it expects sales to rise by between 5% and 7% in 2024 and earnings to increase by 7%-10%. It raised its forecasts for profits growth in 2026, and said it also now expects to notch up sales of more than £38 billion in 2031. The group predicts sales to grow by more than 7% through to 2026 and underlying earnings by more than 11%. ...

How much will GSK's core operating profit grow?

Meanwhile, core operating profit—a closely watched measure of profitability—is expected to grow between 11% and 13%, up from 9% to 11% previously. For core earnings per share, GSK expects growth of 10% to 12% from 8% to 10% previously. ...

How did GSK perform in 2031?

For 2031, GSK increased its original sales guidance by £5 billion to more than £38 billion. Chief executive Emma Walmsley said: “GSK delivered excellent performance in 2023, with clear highlights being the exceptional launch of Arexvy and continued progress in our pipeline. ...